{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T01:44:35Z","timestamp":1784684675508,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Gastrointestinal involvement is almost universal in patients with systemic sclerosis (SSc). Enteric dysmotility, at its most severe, can present with pseudo-obstruction. In this study, we aimed to quantify the prevalence of SSc pseudo-obstruction and evaluate risk factors for its development. In a subgroup of patients requiring admission to hospital for acute episodes of pseudo-obstruction, we evaluated the clinical course and treatments administered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using data from 1969 Australian Scleroderma Cohort Study (ASCS) participants, we performed multivariable logistic regression analysis to identify SSc-specific risk factors for pseudo-obstruction. Descriptive statistics were used to examine the clinical course of patients admitted with pseudo-obstruction at a single ASCS centre.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Pseudo-obstruction occurred uncommonly, affecting 70 (3.56%) ASCS participants. Records of 14 participants with a total of 39 admissions for acute pseudo-obstruction were identified. Pseudo-obstruction was associated with longer disease duration (OR 1.03,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03), bowel dysmotility (OR 4.51,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), small intestinal bacterial overgrowth (OR 2.81, 95% CI (1.00\u20131.05),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), and gastric antral vascular ectasia (OR 2.52, 95% CI 1.28\u20134.94,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Severe diarrhoea, as measured by the UCLA Gastrointestinal 2.0 questionnaire, was the only clinical symptom significantly associated with episodes of pseudo-obstruction (OR 3.39, 95% CI 1.56\u20137.38,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Opioids were more commonly prescribed in patients with pseudo-obstruction but were not significantly associated with pseudo-obstruction in multivariable analysis (OR 1.24, 95% CI 0.62\u20132.48,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.54). Patients with a history of pseudo-obstruction were more likely to require enteral (4.29% vs. 0.21%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) or parenteral nutrition (7.14% vs. 0.16%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pseudo-obstruction is associated with other severe gastrointestinal manifestations and is associated with malnutrition in SSc patients. Future studies are required to assess the impact of treatment of SSc-associated enteric dysmotility to prevent progression to pseudo-obstruction.<\/jats:p>\n                    <jats:p>\n                      <jats:table-wrap>\n                        <jats:table>\n                          <jats:tbody>\n                            <jats:tr>\n                              <jats:td align=\"left\" colspan=\"2\">Key Points\u2022 Pseudo-obstruction is an uncommon manifestation of systemic sclerosis but frequently recurs and is associated with increased mortality.\u2022 Severe diarrhoea and long disease duration are associated with an increased risk of pseudo-obstruction.\u2022 Pseudo-obstruction occurs more commonly in patients with severe enteric dysmotility and gastric antral vascular ectasia (GAVE).<\/jats:td>\n                            <\/jats:tr>\n                          <\/jats:tbody>\n                        <\/jats:table>\n                      <\/jats:table-wrap>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-025-07676-6","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:12:37Z","timestamp":1759313557000},"page":"4541-4551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence, clinical characteristics, and hospital course of systemic sclerosis-associated pseudo-obstruction"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4636-729X","authenticated-orcid":false,"given":"Laura","family":"Ross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyman","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alannah","family":"Quinlivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Proudman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Sahhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene-Siew","family":"Ngian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Host","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Nikpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chamara","family":"Basnayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"7676_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41584-023-00929-1","volume":"19","author":"ZH McMahan","year":"2023","unstructured":"McMahan ZH, Kulkarni S, Chen J et al (2023) Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management. Nature Rev Rheumatol 19:166\u2013181","journal-title":"Nature Rev Rheumatol"},{"key":"7676_CR2","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1093\/rheumatology\/kev393","volume":"55","author":"A Valenzuela","year":"2016","unstructured":"Valenzuela A, Li S, Becker L et al (2016) Intestinal pseudo-obstruction in patients with systemic sclerosis: an analysis of the Nationwide Inpatient Sample. Rheumatology (Oxford) 55:654\u2013658","journal-title":"Rheumatology (Oxford)"},{"key":"7676_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/MCG.0000000000001047","volume":"52","author":"TJ Downes","year":"2018","unstructured":"Downes TJ, Cheruvu MS, Karunaratne TB, De Giorgio R, Farmer AD (2018) Pathophysiology, diagnosis, and management of chronic intestinal pseudo-obstruction. J Clin Gastroenterol 52:477\u2013489","journal-title":"J Clin Gastroenterol"},{"key":"7676_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2019.101635","volume":"40\u201341","author":"G Lindberg","year":"2019","unstructured":"Lindberg G (2019) Pseudo-obstruction, enteric dysmotility and irritable bowel syndrome. Best Pract Res Clin Gastroenterol 40\u201341:101635","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"7676_CR5","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 72:1747\u20131755","journal-title":"Ann Rheum Dis"},{"key":"7676_CR6","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets & pathogenesis. J Rheumatol 15:202\u2013205","journal-title":"J Rheumatol"},{"key":"7676_CR7","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.3899\/jrheum.110225","volume":"38","author":"D Khanna","year":"2011","unstructured":"Khanna D, Furst DE, Maranian P et al (2011) Minimally important differences of the UCLA scleroderma clinical trial consortium gastrointestinal tract instrument. J Rheumatol 38:1920\u20131924","journal-title":"J Rheumatol"},{"key":"7676_CR8","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s10067-020-05325-8","volume":"40","author":"M den Braber-Ymker","year":"2021","unstructured":"den Braber-Ymker M, Vonk MC, Grunberg K, Lammens M, Nagtegaal ID (2021) Intestinal hypomotility in systemic sclerosis: a histological study into the sequence of events. Clin Rheumatol 40:981\u2013990","journal-title":"Clin Rheumatol"},{"key":"7676_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.semarthrit.2019.05.005","volume":"49","author":"E Dein","year":"2019","unstructured":"Dein E, Kuo PL, Hong YS, Hummers LK, Mecoli CA, McMahan ZH (2019) Evaluation of risk factors for pseudo-obstruction in systemic sclerosis. Semin Arthritis Rheum 49:405\u2013410","journal-title":"Semin Arthritis Rheum"},{"key":"7676_CR10","first-page":"2050","volume":"34","author":"E Nishimagi","year":"2007","unstructured":"Nishimagi E, Tochimoto A, Kawaguchi Y et al (2007) Characteristics of patients with early systemic sclerosis and severe gastrointestinal tract involvement. J Rheumatol 34:2050\u20132055","journal-title":"J Rheumatol"},{"key":"7676_CR11","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/art.24734","volume":"61","author":"S Assassi","year":"2009","unstructured":"Assassi S, Del Junco D, Sutter K et al (2009) Clinical and genetic factors predictive of mortality in early systemic sclerosis. Arthritis Rheum 61:1403\u20131411","journal-title":"Arthritis Rheum"},{"key":"7676_CR12","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1136\/ard.2009.111906","volume":"69","author":"FC Arnett","year":"2010","unstructured":"Arnett FC, Gourh P, Shete S et al (2010) Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis 69:822\u2013827","journal-title":"Ann Rheum Dis"},{"key":"7676_CR13","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.14309\/ajg.0000000000000397","volume":"114","author":"JB Brandler","year":"2019","unstructured":"Brandler JB, Sweetser S, Khoshbin K, Babameto M, Prokop LJ, Camilleri M (2019) Colonic manifestations and complications are relatively under-reported in systemic sclerosis: a systematic review. Am J Gastroenterol 114:1847\u20131856","journal-title":"Am J Gastroenterol"},{"key":"7676_CR14","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/acr.24488","volume":"74","author":"ZH McMahan","year":"2022","unstructured":"McMahan ZH, Tucker AE, Perin J et al (2022) Relationship between gastrointestinal transit, Medsger gastrointestinal severity, and University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 symptoms in patients with systemic sclerosis. Arthritis Care Res 74:442\u2013450","journal-title":"Arthritis Care Res"},{"key":"7676_CR15","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3899\/jrheum.131547","volume":"41","author":"C Mecoli","year":"2014","unstructured":"Mecoli C, Purohit S, Sandorfi N, Derk CT (2014) Mortality, recurrence, and hospital course of patients with systemic sclerosis-related acute intestinal pseudo-obstruction. J Rheumatol 41:2049\u20132054","journal-title":"J Rheumatol"},{"key":"7676_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.gtc.2019.08.005","volume":"48","author":"L Pironi","year":"2019","unstructured":"Pironi L, Sasdelli AS (2019) Management of the patient with chronic intestinal pseudo-obstruction and intestinal failure. Gastroenterol Clin North Am 48:513\u2013524","journal-title":"Gastroenterol Clin North Am"},{"key":"7676_CR17","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/ans.13148","volume":"85","author":"MP Bernardi","year":"2015","unstructured":"Bernardi MP, Warrier S, Lynch AC, Heriot AG (2015) Acute and chronic pseudo-obstruction: a current update. ANZ J Surg 85:709\u2013714","journal-title":"ANZ J Surg"},{"key":"7676_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/17474124.2020.1708718","volume":"14","author":"I Aziz","year":"2020","unstructured":"Aziz I, Whitehead WE, Palsson OS, Tornblom H, Simren M (2020) An approach to the diagnosis and management of Rome IV functional disorders of chronic constipation. Expert Rev Gastroenterol Hepatol 14:39\u201346","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"7676_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","volume":"84","author":"F Del Galdo","year":"2025","unstructured":"Del Galdo F, Lescoat A, Conaghan PG et al (2025) EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis 84:29\u201340","journal-title":"Ann Rheum Dis"},{"key":"7676_CR20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/MOG.0000000000000630","volume":"36","author":"L Zenzeri","year":"2020","unstructured":"Zenzeri L, Tambucci R, Quitadamo P, Giorgio V, De Giorgio R, Di Nardo G (2020) Update on chronic intestinal pseudo-obstruction. Curr Opin Gastroenterol 36:230\u2013237","journal-title":"Curr Opin Gastroenterol"},{"key":"7676_CR21","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1111\/ans.18478","volume":"93","author":"BD Wilkie","year":"2023","unstructured":"Wilkie BD, Noori J, Johnston M, Woods R, Keck JO, Behrenbruch C (2023) Pyridostigmine in chronic intestinal pseudo-obstruction - a systematic review. ANZ J Surg 93:2086\u20132091","journal-title":"ANZ J Surg"},{"key":"7676_CR22","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.3748\/wjg.v29.i22.3400","volume":"29","author":"I Efremova","year":"2023","unstructured":"Efremova I, Maslennikov R, Poluektova E et al (2023) Epidemiology of small intestinal bacterial overgrowth. World J Gastroenterol 29:3400\u20133421","journal-title":"World J Gastroenterol"},{"key":"7676_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13075-017-1340-y","volume":"19","author":"B Vigone","year":"2017","unstructured":"Vigone B, Caronni M, Severino A et al (2017) Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. Arthritis Res Ther 19:145","journal-title":"Arthritis Res Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07676-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07676-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07676-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:00:56Z","timestamp":1761660056000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07676-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["7676"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07676-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LH: speaker fees from AbbVie and Janssen unrelated to the submitted work. MN: research grants, honoraria or consultancies from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, and Janssen unrelated to the submitted work. CB: speaker fees from Ferring Pharmaceuticals, Takeda, Falk Pharmaceuticals, and consulting fees from Dr. Reddy\u2019s unrelated to the submitted work. No other authors have any conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"No study author has any competing interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}